[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:acute-lymphoblastic-leukemia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":309,"states":354},"Acute Lymphoblastic Leukemia",182,155,[8,16,23,29,35,42,49,55,61,67,73,78,84,90,96,101,108,114,120,126,132,137,143,150,156,162,168,174,180,186,192,198,204,210,216,222,227,233,238,243,249,255,261,267,273,279,285,291,297,303],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07532525","Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma",[12],"Phase 1","RECRUITING","2026-08-26T02:18:56.409949Z","2026-07-19T19:36:05.074801Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07400029","A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia",[20],"Phase 2","2026-08-26T02:17:17.791881Z","2026-07-05T05:32:16.679314Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04747912","Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)",[20],"2026-08-26T02:18:33.598205Z","2026-06-06T00:48:49.516454Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07586618","First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.",[12],"2026-08-26T02:16:20.336282Z","2026-05-29T15:36:40.197919Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT06051409","A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)",[39],"Phase 3","2026-08-26T02:18:29.369233Z","2026-05-13T02:55:06.404671Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT06308588","Phase I\u002FII Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",[46],"Phase 1\u002FPhase 2","2026-08-26T02:16:17.877565Z","2026-05-05T02:43:29.682278Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT05581030","CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)",[12],"2026-08-26T02:17:39.857430Z","2026-05-05T02:43:29.666329Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT04881240","Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed\u002FRefractory CD19+ Leukemia",[12],"2026-08-26T02:17:57.997171Z","2026-05-05T02:43:29.155602Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06408194","Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies",[12],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:29.029325Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT03263572","Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed\u002FRefractory, Acute Lymphoblastic Leukemia",[20],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:28.640935Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":71,"content_modified":77},"NCT06810583","A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia",[12],"2026-05-05T02:43:28.629308Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT05756322","The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias",[46],"2026-08-26T02:16:11.347936Z","2026-05-05T02:43:27.965604Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06533748","Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma",[20],"2026-08-26T02:17:49.709549Z","2026-05-05T02:43:27.826171Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT07257419","CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+\u002FCD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed\u002FRefractory CD19+ ALL and Lymphoma",[12],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:27.676036Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":21,"content_modified":100},"NCT06847269","CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia",[20],"2026-05-05T02:43:27.418413Z",{"nct_id":102,"title":103,"phases":104,"status":13,"updated_at":106,"content_modified":107},"NCT04877522","Asciminib Roll-over Study",[105],"Phase 4","2026-08-26T02:19:28.327680Z","2026-05-05T02:43:27.182842Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT07294677","CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL\u002FLBL",[46],"2026-08-26T02:15:18.897219Z","2026-05-05T02:43:26.959845Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT06777979","CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:26.924544Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT03571321","Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:17:30.961790Z","2026-05-05T02:43:26.772451Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT05535855","UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1",[12],"2026-08-26T02:16:03.788292Z","2026-05-05T02:35:31.898196Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":118,"content_modified":136},"NCT03104491","Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia",[46],"2026-05-05T02:35:31.864785Z",{"nct_id":138,"title":139,"phases":140,"status":13,"updated_at":141,"content_modified":142},"NCT06287528","A Study of 19-28z\u002FIL-18 in People With Acute Lymphoblastic Leukemia (ALL)",[12],"2026-08-26T02:18:49.989941Z","2026-05-05T02:35:31.697561Z",{"nct_id":144,"title":145,"phases":146,"status":13,"updated_at":148,"content_modified":149},"NCT06735690","Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia",[147],"Early Phase 1","2026-08-26T02:16:04.914942Z","2026-05-05T02:35:31.635862Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT06918431","Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",[20],"2026-08-26T02:15:53.461103Z","2026-04-29T02:57:57.072943Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT05473910","A Phase 1\u002F3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)",[12],"2026-08-26T02:16:50.548894Z","2026-07-19T19:36:05.117931Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT06364423","Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias",[46],"2026-08-26T02:18:24.494016Z","2026-07-05T05:32:16.752213Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT06287944","225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome",[12],"2026-08-26T02:15:23.202838Z","2026-07-05T05:32:16.749077Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT07228741","Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity",[20],"2026-08-26T02:17:16.980188Z","2026-06-16T05:54:07.936307Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT07573111","Phase 1 Dose Escalation Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation",[12],"2026-08-26T02:17:23.750999Z","2026-05-13T02:55:06.778258Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT06704152","BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS",[46],"2026-08-26T02:18:18.766496Z","2026-05-05T02:43:29.733634Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT06289673","Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia\u002FLymphoma",[105],"2026-08-26T02:19:19.975067Z","2026-05-05T02:43:29.703791Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT05909059","CAR T-cell Therapy in Patients With Renal Dysfunction",[20],"2026-08-26T02:16:42.787115Z","2026-05-05T02:43:29.640977Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT05528939","Feasibility\u002FAcceptability of Attentional-Control Training in Survivors",[],"2026-08-26T02:15:37.042762Z","2026-05-05T02:43:29.349678Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT05848687","TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II",[46],"2026-08-26T02:16:24.970704Z","2026-05-05T02:43:29.336397Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT03533816","Expanded\u002FActivated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide",[12],"2026-08-26T02:16:47.762107Z","2026-05-05T02:43:28.956477Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":106,"content_modified":226},"NCT06803745","Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)",[],"2026-05-05T02:43:28.866353Z",{"nct_id":228,"title":229,"phases":230,"status":13,"updated_at":231,"content_modified":232},"NCT01853631","Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)",[12],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.649787Z",{"nct_id":234,"title":235,"phases":236,"status":13,"updated_at":130,"content_modified":237},"NCT04872478","Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed\u002FRefractory AML, ALL, or MPAL",[12],"2026-05-05T02:43:28.121189Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":202,"content_modified":242},"NCT06904482","Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood",[20],"2026-05-05T02:43:27.988984Z",{"nct_id":244,"title":245,"phases":246,"status":13,"updated_at":247,"content_modified":248},"NCT06575296","Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant",[12],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:27.843378Z",{"nct_id":250,"title":251,"phases":252,"status":13,"updated_at":253,"content_modified":254},"NCT02392572","ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome",[46],"2026-08-03T03:46:33.830427Z","2026-05-05T02:43:27.670437Z",{"nct_id":256,"title":257,"phases":258,"status":13,"updated_at":259,"content_modified":260},"NCT06892158","Massage Impact on Sleep in Pediatric Oncology",[],"2026-08-26T02:17:44.240289Z","2026-05-05T02:43:27.492298Z",{"nct_id":262,"title":263,"phases":264,"status":13,"updated_at":265,"content_modified":266},"NCT07155226","Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression",[46],"2026-08-26T02:15:17.167444Z","2026-05-05T02:43:27.256920Z",{"nct_id":268,"title":269,"phases":270,"status":13,"updated_at":271,"content_modified":272},"NCT07356154","A Study of Revumenib and Mezigdomide in People With Leukemia",[46],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:26.921862Z",{"nct_id":274,"title":275,"phases":276,"status":13,"updated_at":277,"content_modified":278},"NCT04195347","Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase",[46],"2026-08-26T02:17:01.714035Z","2026-05-05T02:35:31.900996Z",{"nct_id":280,"title":281,"phases":282,"status":13,"updated_at":283,"content_modified":284},"NCT06195891","Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome",[12],"2026-08-26T02:18:21.216897Z","2026-05-05T02:35:31.631536Z",{"nct_id":286,"title":287,"phases":288,"status":13,"updated_at":289,"content_modified":290},"NCT06227026","Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed\u002FRefractory CD19+ Malignancies",[12],"2026-08-26T02:15:11.740957Z","2026-04-29T02:57:57.116949Z",{"nct_id":292,"title":293,"phases":294,"status":13,"updated_at":295,"content_modified":296},"NCT03670966","211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome",[46],"2026-08-26T02:17:52.450442Z","2026-07-05T05:32:16.772513Z",{"nct_id":298,"title":299,"phases":300,"status":13,"updated_at":301,"content_modified":302},"NCT07566377","Cord Blood Transplantation in Children and Young Adults With Blood Cancer",[20],"2026-08-26T02:15:09.079045Z","2026-05-13T02:55:06.730274Z",{"nct_id":304,"title":305,"phases":306,"status":13,"updated_at":307,"content_modified":308},"NCT07565220","Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies",[12],"2026-08-26T02:16:16.995720Z","2026-05-13T02:55:06.728889Z",[310,314,318,322,326,330,334,337,341,345,348,351],{"biomarker":311,"count":312,"slug":313},"CD19 Gene",16,"cd19-gene",{"biomarker":315,"count":316,"slug":317},"BCR\u002FABL1 Fusion Gene",15,"bcr-abl1-fusion-gene",{"biomarker":319,"count":320,"slug":321},"KMT2A Gene",11,"kmt2a-gene",{"biomarker":323,"count":324,"slug":325},"HLA Complex",9,"hla-complex",{"biomarker":327,"count":328,"slug":329},"CD22 Gene",6,"cd22-gene",{"biomarker":331,"count":332,"slug":333},"NPM1 Gene",5,"npm1-gene",{"biomarker":335,"count":332,"slug":336},"Receptor-Type Tyrosine-Protein Kinase FLT3","receptor-type-tyrosine-protein-kinase-flt3",{"biomarker":338,"count":339,"slug":340},"t(9;22)(q34.1;q11.2)",4,"t-9-22-q34-1-q11-2",{"biomarker":342,"count":343,"slug":344},"KERATIN 31, TYPE I",3,"keratin-31-type-i",{"biomarker":346,"count":343,"slug":347},"MBD5 wt Allele","mbd5-wt-allele",{"biomarker":349,"count":343,"slug":350},"MS4A1 Gene","ms4a1-gene",{"biomarker":352,"count":343,"slug":353},"NUP98 Gene","nup98-gene",[355,359,363,367,371,375,379,382,386,389,393,397,401,405,409,412,415,419,423,427,430,433,436,440],{"state":356,"count":357,"slug":358},"California",48,"california",{"state":360,"count":361,"slug":362},"New York",41,"new-york",{"state":364,"count":365,"slug":366},"Texas",37,"texas",{"state":368,"count":369,"slug":370},"Tennessee",30,"tennessee",{"state":372,"count":373,"slug":374},"North Carolina",25,"north-carolina",{"state":376,"count":377,"slug":378},"Florida",24,"florida",{"state":380,"count":377,"slug":381},"Pennsylvania","pennsylvania",{"state":383,"count":384,"slug":385},"Illinois",23,"illinois",{"state":387,"count":384,"slug":388},"Ohio","ohio",{"state":390,"count":391,"slug":392},"Massachusetts",21,"massachusetts",{"state":394,"count":395,"slug":396},"Washington",20,"washington",{"state":398,"count":399,"slug":400},"Georgia",19,"georgia",{"state":402,"count":403,"slug":404},"Maryland",18,"maryland",{"state":406,"count":407,"slug":408},"Minnesota",17,"minnesota",{"state":410,"count":316,"slug":411},"New Jersey","new-jersey",{"state":413,"count":316,"slug":414},"Wisconsin","wisconsin",{"state":416,"count":417,"slug":418},"Michigan",14,"michigan",{"state":420,"count":421,"slug":422},"Oregon",13,"oregon",{"state":424,"count":425,"slug":426},"District of Columbia",12,"district-of-columbia",{"state":428,"count":425,"slug":429},"Missouri","missouri",{"state":431,"count":320,"slug":432},"Colorado","colorado",{"state":434,"count":320,"slug":435},"Utah","utah",{"state":437,"count":438,"slug":439},"Alabama",10,"alabama",{"state":441,"count":324,"slug":442},"Oklahoma","oklahoma"]